The experiences a baby has with her caregivers are crucial to this early wiring and pruning and enable millions and millions of new connections in the brain to be made. This rapid brain growth and circuitry have been estimated at an astounding rate of 700–1000 synapse connections per second in this period. By the age of three, a child’s brain has reached almost 90% of its adult size. The most important stage for brain development is the beginning of life, starting in the womb and then the first year of life.
It’s more complicated than a computer, in fact it’s most complicated object in the known universe. The human brain is an amazing organ made up of over 100 billion brain cells that each connect to over 7000 other brain cells. Well, evidence from the new branch of science called epigenetics is reporting that this long-term emotional inoculation might be possible.
Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.Imagine if the hugs, lullabies and smiles from parents could inoculate babies against heartbreak, adolescent angst and even help them pass their exams decades later. The company assumes no duty to update the information to reflect subsequent developments. The information contained in this website was current as of the date presented. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (No Duty to Update The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Risks and uncertainties include but are not limited to, general industry conditions and competition general economic factors, including interest rate and currency exchange rate fluctuations the impact of the recent global outbreak of novel coronavirus disease (COVID-19) the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally global trends toward health care cost containment technological advances, new products and patents attained by competitors challenges inherent in new product development, including obtaining regulatory approval the company’s ability to accurately predict future market conditions manufacturing difficulties or delays financial instability of international economies and sovereign risk dependence on the effectiveness of the company’s patents and other protections for innovative products and the exposure to litigation, including patent litigation, and/or regulatory actions. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. Private Securities Litigation Reform Act of 1995. This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S.